Summary & Overview

HCPCS J9206: Injection, Irinotecan 20 mg

HCPCS Level II code J9206 denotes a 20 mg unit of injectable irinotecan, a systemic chemotherapy agent used in numerous oncology regimens. As a drug-specific HCPCS code, J9206 is used on medical claims to report the dispensing and billing of irinotecan in outpatient settings. This code matters nationally because oncology drug billing drives significant outpatient drug spend, affects site-of-care cost differences, and is subject to payer-specific coverage and payment policies.

Key payers in the national profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of billing context for irinotecan, common payer coverage considerations, and the types of benchmarks and policy items typically tracked for HCPCS drug codes, including reimbursement units, administration settings, and program-level payment rules. The summary highlights where to expect variation: site-of-service pricing, bundled vs. pass-through payment determinations, and payer edits that influence claim adjudication.

The publication provides practical reference information: an explanation of the code and service type, expected sites of care, common modifiers used with HCPCS drug billing (listed separately), and guidance on where to locate payer-specific policy language. Data not provided in the input is identified as unavailable so readers understand limits of the source material.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ9206HCPCS Level IIirinotecanchemotherapyoncologyinjectable-drugoutpatient-infusiondrug-billingmedical-claims

Billing Code Overview

HCPCS Level II code J9206 represents injection, irinotecan, 20 mg. The service is a chemotherapy drug administration supplied as a billed drug unit of irinotecan in 20 mg increments. The typical site of service for this HCPCS Level II code is hospital outpatient departments, physician offices, and ambulatory infusion centers where intravenous chemotherapy agents are prepared and administered.

Service type: Chemotherapy drug (injectable antineoplastic agent)

Typical site of service: Hospital outpatient department, physician office, ambulatory infusion center

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with metastatic colorectal cancer presents to an outpatient oncology infusion center for systemic chemotherapy. The clinical plan orders irinotecan administered intravenously as part of a combination regimen (for example FOLFIRI) following baseline assessment by the oncology nurse: vital signs, review of recent labs (complete blood count, comprehensive metabolic panel, and liver function tests), and verification of patient identity and consent. The pharmacist compounds the irinotecan dose from vial strength consistent with J9206 (Irinotecan, 20 mg units) and prepares the infusion in an appropriate infusion bag. The patient is attached to an infusion pump and monitored for infusion-related reactions, cholinergic symptoms, and delayed diarrhea. Antiemetic prophylaxis is given per protocol and loperamide instructions are provided for delayed diarrhea at discharge. Documentation includes indication, drug lot numbers, dose (converted to mg and billed in units of J9206), administration route, start and stop times, site of service, and any applicable modifier (for example, modifier JW if discarded drug is not billable). Typical site of service is an outpatient hospital-based or freestanding infusion center; administration may also occur in an office-based oncology practice. Common payors for authorization and claims include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered to any patient	Use when a portion of compounded irinotecan was discarded and cannot be billed; report with the HCPCS drug code when required.
`JZ`	No drug administered (single-dose vial wasted/missed)	Use when the ordered irinotecan was not administered and no dose was given.
`-59`	Distinct procedural service	Use when a separately identifiable service related to chemotherapy administration is performed the same day and must be distinguished (alternate modifier forms such as `XS`/`XU` may be used depending on payer).
`XS`	Separate structure	Use to indicate a service performed on a separate site or organ system when distinguishing related services for billing.
`XU`	Unusual non-overlapping service	Use when billing a service that is distinct because it does not overlap usual components of another service provided the same day.
`76`	Repeat procedure or service by same physician	Use when the irinotecan infusion (or associated infusion code) is repeated later the same day by the same practitioner.
`77`	Repeat procedure by another physician (not in provided list but commonly paired)	Data not available in the input.
`25`	Significant, separately identifiable evaluation and management service	Use when an E/M is performed on the same day as chemotherapy infusion for a condition separate from the infusion visit.
`52`	Reduced services	Use when the full chemotherapy administration was partially reduced or not completed for clinical reasons.
`53`	Discontinued procedure	Use when the infusion is started but discontinued due to adverse event and full service cannot be completed.
`59`	Distinct procedural service (alternate to `-59`)	Use per payer guidance to indicate distinct services on the same day.
`62`	Two surgeons	Use when two physicians of the same specialty are involved in a surgical setting related to the cancer care (rare for infusion billing).
`JC`	Not applicable in provided list.

Taxonomy Code	Specialty	Notes
`2084P0800X`	Medical Oncology	Oncologists who order and direct systemic chemotherapy.
`363L00000X`	Hematology/Oncology	Physicians specializing in combined hematology and oncology care; frequently manage irinotecan regimens.
`207RC0000X`	Radiation Oncology	May be involved in multidisciplinary cancer care when coordinating systemic therapy with radiation.
`177N00000X`	Nurse Practitioner	Advanced practice providers who may order and manage chemotherapy under protocol.
`363A00000X`	Oncology Nurse	Infusion nurses credentialed to administer cytotoxic chemotherapy and manage infusion reactions.

Note: Modifier selections focus on those most commonly applicable to chemotherapy drug administration billing. Use payer-specific guidance for final modifier selection.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.9`	Malignant neoplasm of colon, unspecified	Colorectal cancer is a primary indication for irinotecan-containing regimens such as FOLFIRI.
`C20`	Malignant neoplasm of rectum	Rectal adenocarcinoma may be treated with systemic irinotecan in metastatic or adjuvant settings.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Hepatic metastases from colorectal primary often prompt systemic chemotherapy including irinotecan.
`C77.0`	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Metastatic nodal disease can be part of staging where systemic therapy is indicated.
`Z51.11`	Encounter for antineoplastic chemotherapy	Billing must reflect encounter for chemotherapy administration; used as a secondary diagnosis to indicate purpose of visit.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single drug infusion	Common code for IV infusion of irinotecan when administered as a single-agent infusion lasting up to 1 hour; billed alongside the drug HCPCS units.
`96415`	Chemotherapy administration, intravenous infusion technique; each additional hour	Used when irinotecan infusion or infusion-related observation extends beyond the initial hour.
`96417`	Chemotherapy administration, each additional sequential infusion of a new drug, up to 1 hour	Applied when irinotecan is administered as an additional drug in a multi-drug infusion sequence.
`36415`	Collection of venous blood by venipuncture	Commonly performed prior to chemotherapy to obtain labs required for safe dosing (CBC, chemistries).
`96360`	Intravenous infusion for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	May be used for non-chemotherapy infusions related to supportive care; less common for primary irinotecan billing.
`99070`	Supplies and materials (except spectacles) used for patient care	Used for non-standard supplies associated with infusion that are not included in the administration code; payer rules vary.